Finerenone (Kerendia®). HTA ID: 22012

Assessment Status NCPE Assessment Process Complete
HTA ID 22012
Drug Finerenone
Brand Kerendia®
Indication For the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
Assessment Process
Rapid review commissioned 21/02/2022
Rapid review completed 15/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of finerenone compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 01/04/2022
Pre-submission consultation with Applicant 24/05/2022
Full submission received from Applicant 10/11/2022
Preliminary review sent to Applicant 24/02/2023
NCPE assessment re-commenced 29/03/2023
Follow-up to preliminary review sent to Applicant 08/05/2023
NCPE assessment re-commenced 18/05/2023
Factual accuracy sent to Applicant 12/06/2023
NCPE assessment re-commenced 04/07/2023
NCPE assessment completed 22/08/2023
NCPE assessment outcome The NCPE recommends that finerenone (Kerendia®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013